Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics as the Chinese biotech tacks on preclinical neurological assets to its varied portfolio. Shanghai-based OTR raised the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback